NEW YORK, Nov. 1, 2023 /PRNewswire/ -- Jona, a technology company on a mission to reveal the relationship between the microbiome and health, today launched with $5 million in funding led by Breyer Capital and Meridian Street Capital. Beginning today, consumers and providers can now purchase and use Jona's at-home microbiome profiling kit, which uses AI to analyze an individual's microbiome and deliver actionable insights that empower individuals to take a more proactive approach to their health in an era of rising chronic illness..

纽约，2023年11月1日/PRNewswire/-Jona是一家技术公司，致力于揭示微生物组与健康之间的关系，今天由Breyer Capital和Meridian Street Capital领导的500万美元资金启动。从今天开始，消费者和供应商现在可以购买和使用Jona的家庭微生物组分析工具包，该工具包使用人工智能分析个人的微生物组，并提供可操作的见解，使个人能够在慢性病发病率上升的时代采取更积极主动的方法来健康。。

Continue Reading

继续阅读

Jona sets new standard of personalized health using AI to reveal the relationship between the gut microbiome and health

Jona使用AI设定了个性化健康的新标准，以揭示肠道微生物组与健康之间的关系

Post this

发布这个

Jona Microbiome Profiling Kit and Report Highlights

Jona微生物组分析工具包和报告亮点

'I'm thrilled to once again partner with Leo Grady, an incredible operator whose career has been built on finding effective ways to merge AI and healthcare,' said Jim Breyer, CEO and Founder of Breyer Capital. 'We believe that Jona has enormous potential to directly impact patient care. With its innovative use of LLMs and some of the most advanced applications of generative AI we've seen, the company will change how we think about the microbiome and the future of human health.'.

“我很高兴再次与Leo Grady合作，Leo Grady是一位令人难以置信的运营商，他的职业生涯建立在寻找有效的人工智能和医疗保健相结合的基础上，”Breyer Capital首席执行官兼创始人Jim Breyer说。'我们相信Jona有直接影响患者护理的巨大潜力。通过创新使用LLMs和我们所看到的生成AI的一些最先进的应用，公司将改变我们对微生物组和人类健康未来的思考。

According to NIH research, 60-70 million Americans are affected by GI disorders1. In addition, the American Autoimmune Related Diseases Association (AARDA) reports that as many as 50 million Americans are living with an autoimmune disease costing billions of healthcare spending each year. Many of these individuals struggle to find a diagnosis, relieve symptoms, and find effective therapies. Jona's platform aims to equip these individuals with the latest scientific knowledge to discover root causes and develop effective treatment plans..

根据美国国立卫生研究院的研究，有6000万到7000万美国人受到胃肠道疾病的影响1。此外，美国自身免疫相关疾病协会（AARDA）报告称，多达5000万美国人患有自身免疫性疾病，每年花费数十亿美元的医疗支出。这些人中有许多人努力寻找诊断，缓解症状并找到有效的治疗方法。乔纳的平台旨在为这些人提供最新的科学知识，以发现根本原因并制定有效的治疗计划。。

Jona is founded by Leo Grady, PhD, who is internationally recognized for his work to deliver AI in healthcare for nearly 20 years at pioneering bay area startups (HeartFlow), multinational medical companies (Siemens) and, most recently, as CEO of Paige.ai. He has built FDA approved AI applications for many areas of medicine, including radiology, cardiology and pathology that are now incorporated into standard care.'My family members suffer from chronic conditions like Crohn's, colitis and celiac disease.

Jona由Leo Grady博士创立，他因在开创性的湾区初创公司（HeartFlow），跨国医疗公司（西门子）以及最近担任Paige首席执行官的工作在医疗保健领域提供AI近20年而获得国际认可。他已经为许多医学领域建立了FDA批准的AI应用程序，包括放射学，心脏病学和病理学，现已纳入标准护理中。”我的家人患有克罗恩病，结肠炎和乳糜泻等慢性疾病。

They've all had their microbiome tested in hopes of finding relief, but the results showed arbitrary scores that were not justified with science and seemed designed to sell supplements. It was frustrating because I knew that microbiome science was advancing rapidly and I saw the opportunity for AI to make the microbiome literature more accessible, interpretable and transparent for consumers and providers,' said Leo Grady, PhD, CEO and Founder of Jona.

他们都进行了微生物组测试，希望找到缓解，但结果显示任意分数，科学不合理，似乎设计销售补充剂。乔纳的首席执行官兼创始人利奥·格雷迪（Leo Grady）博士说，令人沮丧的是，我知道微生物组科学正在迅速发展，我看到了人工智能使消费者和提供者更容易获得，可解释和透明的微生物组文献的机会。

'Launching this company is a culmination of my lived experiences and a lifelong career in artificial intelligence and healthcare.'Jona has developed a proprietary Large Language Model (LLM) to interpret an individual's gut microbiome and generate a personalized summary of the entire scientific literature based on their unique microbiome profile.

“推出这家公司是我在人工智能和医疗保健领域的生活经验和终身职业生涯的高潮。”Jona开发了专有的大型语言模型（LLM）来解释个体的肠道微生物群，并根据其独特的微生物群特征对整个科学文献进行个性化总结。

The first product is an easy at-home microbiome profiling kit that sequences the microbes in an individual's gut microbiome. Jona uses this LLM to generate a personalized interactive report with associations to conditions, symptoms, food sensitivities and produces actionable insights on food, diet and lifestyle modifications based on their health goals.

第一款产品是一款简单的家用微生物组分析试剂盒，可对个体肠道微生物组中的微生物进行测序。Jona使用此LLM生成个性化的交互式报告，其中包含与疾病，症状，食物敏感性的关联，并根据其健康目标对食物，饮食和生活方式进行修改。

With Jona, providers can now keep up with and take action on all the latest science as they treat their patients more comprehensiv.

通过Jona，供应商现在可以跟上所有最新的科学并采取行动，因为他们可以更全面地对待患者。